Denosumab Significantly Increases DXA BMD at Both Trabecular and Cortical Sites: Results From the FREEDOM Study
Michael A. Bolognese, Cesar Libanati(Amgen (United States)), Michael R. McClung(Bone Health and Osteoporosis Foundation), Alfred H. Moffett(Lake OB/GYN Associates of Mid-Florida), Maria Luisa Brandi(Vita-Salute San Raffaele University), Kurt Lippuner(University of Bern), Andrea Wang(Amgen (United States)), Christence Stubbe Teglbjærg(Center for Clinical & Basic Research), R Lorenc(Supélec), Arne Høiseth, P. Lakatos(Semmelweis University), José Zanchetta(Universidad del Salvador)
Cited by 64
Related Papers
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
|New England Journal of Medicine|2014|1.2k
Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis
|Journal of Bone and Mineral Research|2004|1.2k
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
|New England Journal of Medicine|2014|712